Clinical PET/MRI Work Package 3:

Early and late onset cognitive impairment

Asta Håberg

Principal Investigator

Geir Bråthen

Principal Investigator

Work package 1:

1 in 8 men will have prostate cancer in their lives. Molecular imaging may offer huge benefits in all stages of the diagnostic work-up, and PET imaging using the tracer prostate specific membrane antigen (PSMA) has shown promising results. This WP aims to establish nation-wide protocols for PSMA-PET (in combination with hybrid MRI or CT)…

Read More...

Work package 2:

MRI is used in clinical routine for diagnosing brain tumors, but has limitations in identifying tumor grade, true tumor extension and differentiating viable tumor tissue from treatment induced changes and recurrences. Many brain tumors express increased levels of amino acid transport, which can be imaged with a PET scanner using amino acid radiotracers. Using both…

Read More...

Work package 3:

Read More...

Work package 4:

In WP4 we will establish the clinical workflow for PET- and MRI-based radiotherapy. We will acquire PET and MR images prior to and during radiotherapy and develop new concepts for image-based biologically adaptive radiotherapy, both based on state-of-the-art photon-based radiotherapy and also proton therapy, which soon will be available for cancer patients in Norway. Our…

Read More...

Work package 5:

In the machine learning work package, we aim to develop and validate new methods that exploit the quantitative nature of the PET and MR images. We will develop a pipeline for pre-processing and quality assurance of the acquired images, as well as a toolbox with machine learning algorithms focusing on region classification and detection of…

Read More...